Skip to Main Content

Paper Details

Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
Eur J Cancer
6
2021
Author NameAffiliation
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University
Fred SaadCentre Hospitalier de l'Universite de Montreal
Eleni EfstathiouMD Anderson Cancer Center
Cora N SternbergEnglander Institute for Precision Medicine, Meyer Cancer Center
  • 1 - 4

Datasets

Release 1.2